Loading…
This event has ended. Create your own event → Check it out
This event has ended. Create your own
View analytic
Tuesday, September 19
 

8:30am

Registration Open
Tuesday September 19, 2017 8:30am - 5:00pm
Foyer Courtyard by Marriot Madrid Princesa Hotel

10:00am

Welcome Coffee Break
Tuesday September 19, 2017 10:00am - 10:45am
Foyer Courtyard by Marriot Madrid Princesa Hotel

10:00am

Exhibition Open
Tuesday September 19, 2017 10:00am - 8:00pm
Rosales 2+3 Courtyard by Marriot Madrid Princesa Hotel

10:45am

Welcome and Opening Remarks
Moderators
avatar for Maria Montoya

Maria Montoya

Head of Cellomics Unit, Centro Nacional de Investigaciones Cardiovasculares (CNIC)

Speakers
avatar for Vicki Loise

Vicki Loise

CEO, SLAS


Tuesday September 19, 2017 10:45am - 11:05am
Rosales I Courtyard by Marriot Madrid Princesa Hotel

11:00am

Posters on Display in Exhibition
Posters will be displayed on boards within the exhibition througout the day.  Please browse at your leisure. 

Presenters are available for questions on Wednesday 20 September from 2:40-3:45 p.m.

Poster 01 – In Vitro Assessment of Drug Effects on Human iPSC-Derived Cardiac Spheroid Cultures; Geoff Dance, Molecular Devices

 

Poster 02 – Monitoring altered Ca2+ signalling in breast cancer cells with a high-content imaging model of intracellular Ca2+ dynamics using genetically encoded calcium indicators expressed in MDA-MB-231 breast cancer cells; John Bassett, School of Pharmacy, The University of Queensland

 

Poster 03 – Using cell-based high-content screening in combination with X-irradiation for the identification of novel Glioblastoma radiosensitizing agents; Aurianne Lescure, Institut Curie - Translational Research Department

 

Poster 04 – Automated quantitative imaging tools for the study of organelle homeostasis and interorganelle communication; Miguel Sanchez-Alvarez, CNIC

 

Poster 05 – CANCELLED: High-content screening: picturing microRNAs in cardiovascular diseases; Miguel Mano, University of Coimbra, Portugal

 

Poster 06 – High-Content High-Throughput Assays for Morphological Characterization of Neuronal Development in 3D Matrix Using Human iPSC-Derived Neuronal Cultures; Alexandre Fouassier, Axiogenesis AG

 

Poster 07 – High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of recurrent glioblastoma; Jessica Taylor, University of Manchester

 

Poster 08 – Harnessing complexity for easy and robust gene silencing with siPOOLs; Catherine Goh, siTOOLs Biotech GmbH

 

Poster 09 – An Innovative Workflow for Practical Use of Deep Learning in Image-based Research; Stephan Steigele, Genedata AG

 

Poster 10 – A 3D High-Content Screening assay as new model system for polycystic kidney disease; Hester Bange, Leiden University/OcellO

 

Poster 11 – High Content Screening cell based assays for deciphering mechanotransduction-driven mechanisms of tumour invasion; Antonio Quílez-Álvarez, CNIC

 

Poster 12 – The Phenomics Discovery Initiative (PDi) – A Model for Maximising the Translational Impact of Biological Research; Denise Barrault, National Phenotypic Screening Centre - NPSC


Poster 13 –

CANCELLED: 

High Trhoughput target miRNA Screening; Sarantis Chlamydas, Active Motif

 

Poster 14 – The ZeCardio platform: High-throughput cardiotoxicity screening with zebrafish embryos; Sylvia Dyballa, ZeClinics SL

 

Poster 15 – Adoption of High Content Imaging Capabilities in Support of Integrated Drug Discovery Programmes; Marie Fisher, Sygnature Discovery

 

Poster 16 – A High Content Imaging Platform to Advance Target and Compound Validation Imaging Spines and Synapses for Neurological Disorders; Tim Kroecher, Evotec AG

 

Poster 17 – Establishment of breast cancer cells panel for drug repurposing; Carlos Marugán, Lilly

 

Poster 18 – Cell Health Assay Data from a Phenotypic Screen Correlates with Reported Liver Toxicity for FDA Approved Compounds; Michelle Newman, LifeArc

 

Poster 19 – HIGH CONTENT BIOIMAGING IN DRUG DISCOVERY AND SAFETY AT MEDINA; Carmen Ramos, Fundación Medina

 

Poster 20 – A high-throughput high-content in vitro primary cell screen for novel anti-fibrotics; Amy Sawtell, UCB

 

Poster 21 – A High Content Platform for In Vivo Imaging Studies: Characterization of HTT Inclusions in the zQ175 Mouse Model of Huntington´s Disease; Carina Wollnik, Evotec AG

 

Poster 22 – High Throughput Multiplexed Apoptosis Assays Using the Labcyte Echo® Liquid Handler and the IntelliCyt iQue® Screener HD; Aurore Lejeune-Dodge, Labcyte GmbH

 

Poster 23 – Image-based compound profiling in cell based assays; Saman Honarnejad, Pivot Park Screening Centre

 

Poster 24 – CANCELLED BioDataAnalysis CellAnalyzer uncovers complex cellular phenotypes of infection; Mario Emmenlauer, BioDataAnalysis GmbH

 

Poster 25 – TUMOR CELL INVASION ESTIMATION FROM 3D BIOIMAGE USING GEOMETRICAL INFORMATION AND UNSUPERVISED MACHINE LEARNING FOR HCS; Laura Fernández-de-Manuel, Centro Nacional de Investigaciones Cardiovasculares

 

Poster 26 – Analysis of high-dimensional transcriptomics data yields gene networks with high phenotypic discrimination power; Víctor Jiménez-Jiménez, CNIC

 

Poster 27 – Identification and correction of spatial bias are essential for obtaining quality data in high-throughput screening technologies; Bogdan Mazoure, McGill University and Université du Québec à Montréal

 

Poster 28 – High Performance Computing for High Content Screening Image Analysis – A Proof of Concept; Christian Schueller, PerkinElmer

 

Poster 29 – CANCELLED: 3D brain model of iPSC-derived neurons and glia for high-throughput neurotoxicity screening; Henriette Lanz, Mimetas


Poster 30 – High Content Imaging of 3D Cellular Models to Improve Drug Toxicity Risk Assessment, James Pilling, AstraZeneca

Tuesday September 19, 2017 11:00am - 8:00pm
Rosales 2+3 Courtyard by Marriot Madrid Princesa Hotel

11:05am

Session 1: Technology
Microscopy is fast evolving field with development in resolution, imaging modalities, flexibility of acquisition and much more. This session will show how some of these exciting advances are being applied in automated screening setups to allow screening more complex cellular systems for higher clinical relevance.

11:05 - 11:30:
Droplet-Microarray – a miniaturized platform for high throughput screenings
Anna Popova, Institute for Toxicology and Genetics, Karlsruhe Institute of Technology

Phenotypic high throughput screening (HTS) of live cells is a methodology that lies at the basis of fundamental research, drug discovery and toxicology. The main problematic of screenings in our days lies in relatively large volumes per experiment and at the same time a need for higher throughout. Miniaturization of high throughput screenings has been a major trend in past years. Since further miniaturization of microtiter plates is not possible, alternative technologies are emerging to address this problem. Here we present a Droplet-Microarray (DMA) platform - a novel miniaturized platform for HTS of live cells. DMA consists of an array of superhydrophilic spots on superhydrophobic background. Due to extreme difference in wettability between superhydrophilic and superhydrophobic areas cell suspension applied on such surface spontaneously splits in array of homogeneous separated droplets of nL volumes, enabling pipetting-free seeding of cells. We have developed protocols for parallel addition of compounds and reagents simultaneously to the whole array without a need for pipetting of each individual compartment. The DMA platform is transparent and compatible with all kinds of microscopy. In addition, the DMA has dimensions of microscope glass slide or microtiter plate and, therefore, is compatible with all existing microscopes. All the standard protocols including staining, fixation and immunofluorescence can be performed on DMA platform, making it easy to incorporate it into existing screening workflows. In the past years we have evaluated DMA platform for cell-based screening applications. We successfully cultured over 10 different adherent and suspension cell lines, stem cells and primary patient-derived cells in miniaturized format. We have established protocols for transfection and compound treatment of cells on the DMA platform. We optimized procedures for staining, fixation and microscopy of cells of suspension and adherent nature. We tested DMA platform in a proof-of-concept screen on primary patient-derived tumor cells with antineoplastic compounds. We evaluated DMA platform for screening of cells in 3D environments by means of hydrogels, spheroids and embryonic bodies. Moreover, we further extended the portfolio of applications of DMA platform to whole – organism screenings. Using DMA platform we created single-embryo-array where single zebrafish embryo is trapped in an individual droplet, and evaluated this array for toxicity screening applications. Single-embryo-array based on the DMA principle enables detailed microscopic analysis of embryos, which are fixed in particular position in array format, significantly simplifying imaging process and image analysis of live animals. We believe that DMA technology carries a great potential to be adopted for various high content screening applications. On one hand, it is flexible and universal due to its compatibility with various cell types, different functional assays, standard protocols and all types of microscopy. On the other hand, it is highly miniaturized (3-80 nL) and pipetting-free. Thus, the DMA platform is a chip technology for cell-based assays that enables miniaturized and parallelized high throughput screenings of live cells in 2D and 3D, as well as whole-organisms.

11:30 - 12:00:
Applications of non-invasive phenotypic screens using label free imaging by digital holography; three selected examples
Gerardo Turcatti, EPFL 

In the fast evolving field of screening by imaging, a main challenge is to conciliate complex models or assays with more in vivo relevance and throughput. In this context, we are developing assays with representative cells or models amenable to screening using holographic microscopy (DHM) for imaging cells. DHM is a label-free interferometric microscopy technique, which provides a quantitative measurement of the optical path length. It is a two-step process where a hologram consisting of an interference pattern is first recorded on a digital camera and the quantitative phase images are reconstructed numerically using a specific algorithm. We illustrate here three phenotypic screening applications using DHM as imaging read-out: a) a drug screening method for adipocytic differentiation through lipid quantification b) a screen for quantification of cardiomyocytes beating dynamics c) a screening assay for measuring trans-epithelial fluxes in CFTR mutations using gastrointestinal-derived organoids.

12:00 - 12:30:
Cancer organoids for screening of chemotherapeutics and personalized medicine
Francesco Pampaloni, Buchmann Institute for Molecular Life Sciences (BMLS)

Three-dimensional (3D) cell cultures allows establishing physiologically relevant in vitro tissue models, which are of great interest for both industry and clinical research.  In my talk, I describe two 3D cell culture platforms for drug screening based on live fluorescent microscopy recently developed in our group. The first platform is based on U343 glioma 3D multicellular spheroids, which represent a realistic brain cancer model. With the U343 spheroids we established a drug screening pipeline for the identification of autophagy modulators. Since the autophagic flux is often dysregulated in cancer, the discovery of novel autophagy modulating drugs is of great clinical relevance. This screening assay with 3D tumor spheroids is robust, reproducible and scalable and represents a valuable tool for both basic research and pharmaceutical industry [1].The second drug screening platform uses hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) stem cell organoids. The tumor stem cell organoids are obtained from liver biopsies and can be virtually limitless expanded in culture [2]. I illustrate the pros and contra of this new technology and our pipeline for the testing of chemotherapeutics with high-throughput microscopy, discuss realistic approaches for a personalized cancer therapy, and show first data recorded with Light Sheet Fluorescence Microscopy (LSFM). 

12:30 - 13:00:
Combining high-content imaging and pathway profiling technologies to advance in vitro pharmacogenomics and discovery of novel drug combinations
Neil Carragher, Institute of Genetics and Molecular MedicineUniversity of Edinburgh

Recent advances in high-content screening, CRISPR/Cas-based genome editing and induced pluripotent stem cell technologies are converging to stimulate the new discipline of Phenomics Drug Discovery. I will describe how Phenomics Drug Discovery incorporates state-of-the-art imaging, genomics, proteomics and informatics tools to explore drug mechanism-of-action (MOA) studies across genetically defined in vitro cell models. We demonstrate how multiparametric high content screening assays combined with novel image-informatics and machine learning methods advance in vitro pharmacogenomic studies across a broader variety of phenotypes, disease models and therapeutic classes. We also demonstrate how ultrasensitive Reverse Phase Protein Microarray (RPPA) technologies can combine with imaging to characterize drug MOA at the post-translational pathway network level. Finally, I present recent examples of how our Phenomics Drug Discovery platform enabled the rapid discovery of a novel orally-available, ATP-competitive, kinase inhibitor and novel drug combinations which display potent anti-tumour activity across 2D, 3D and in vivo models.

13:00 - 13:30:
Multiscale cytometry and regulation of 3D cell cultures on a chip
Charles Baroud, Ecole Polytechnique

Three-dimensional cell culture is emerging as a more relevant alternative to the traditional two-dimensional format. Yet the ability to perform cytometry at the single cell level on intact three-dimensional spheroids or together with temporal regulation of the cell microenvironment remains limited. I will describe a microfluidic platform to perform high-density three-dimensional culture, controlled stimulation, and observation in a single chip. The method extends the capabilities of droplet microfluidics for performing long-term culture of adherent cells. Using arrays of 500 spheroids per chip, in-situ immunocytochemistry and image analysis provide multiscale cytometry that yields information at the population scale, at the scale of 10,000 or more single spheroids, and nearly 1,000,000 single cells. This allows us to correlate functionality with cellular location within the spheroids and the local structure. Also, an individual spheroid can be extracted for further analysis or culturing. Then by combining this approach with a more advanced droplet handling approach, I will demonstrate how a complete drug response curve can be obtained in a single sweep on a chip. This approach will enable a shift towards quantitative studies on three-dimensional cultures, under dynamic conditions, with implications for stem cells, organs-on-chips, or cancer...

Speakers
avatar for Charles Baroud

Charles Baroud

Ecole Polytechnique
Charles Baroud was trained as a physicist and engineer at MIT, then received a PhD at the University of Texas at Austin. Since then he has founded and now leads the microfluidics group at Ecole Polytechnique in Paris. The group has performed fundamental fluid dynamics research on... Read More →
NC

Neil Carragher

Professor Neil Carragher graduated from the University of Aberdeen, Scotland UK in 1992 with a B.Sc Honours degree in “Cell and Immunobiology”.  He then took up a position within industry at the Yamanouchi Research Institute (now Astellas Pharma), Oxford, England UK where he also gained his PhD. He then held consecutive postdoctoral positions within the Department of Pathology, University of Washington, Seattle, USA and at the Beatson Institute for Cancer Research, Glasgow, Scotland UK. In 2004 Neil returned to the pharmaceutical industry as Principal Scientist with AstraZeneca where he pioneered early multiparametric high-content phenotypic screening approaches. In 2010 he once again made the career switch from industry to academia and took up the post of Principal Investigator of Drug Discovery at the University of Edinburgh. Primary research interests include advancing high-content analysis, phenotypic screening, Reverse Phase Protein Array technology, drug combinations and cancer drug... Read More →
avatar for Francesco Pampaloni

Francesco Pampaloni

Francesco Pampaloni is staff scientist with permanent position at the Buchmann Institute for Molecular Life Sciences (BMLS) in Frankfurt am Main (Germany). He leads the research on three-dimensional cell cultures and he is coordinator and scientific manager of the EU Horizon 2020 project LSFM4LIFE. He graduated in Physical Chemistry at the University of Florence (Italy). Awarded with an EU Marie-Curie Fellowship programme, he moved to the University of Regensburg (Germany), where he obtained his Ph.D. with excellence with a work on Optical Force Microscopy. From 2003 to 2009 post-doc and staff scientist at EMBL Heidelberg (Germany). Since 2010 at the Buchmann Institute for Molecular Life Sciences (BMLS) of the Goethe University Frankfurt. He authored 40+ publications and four patents. He is main inventor and driving force of the High-Throughput LSFM (HT-LSFM) and the Tissue Culture LSFM... Read More →
avatar for Anna Popova

Anna Popova

Institute for Toxicology and Genetics, Karlsruhe Institute of Technology
avatar for Gerardo Turcatti

Gerardo Turcatti

Director of the Biomolecular Screening Facility, EPFL
Dr. Gerardo Turcatti directs the Biomolecular Screening Facility (BSF) he created at the EPFL in 2006. In the frame of the National program NCCR-Chemical Biology, he leads the project ‘ACCESS’ ‘An Academic Chemical Screening Platform for Switzerland’ since 2011. Previously he co-founded and acted as CTO of Manteia S.A., a Swiss-based company that developed revolutionary high throughput DNA sequencing technologies currently commercialized by Illumina Inc. Prior to this experience, Dr Turcatti had a long multidisciplinary career in... Read More →


Tuesday September 19, 2017 11:05am - 1:30pm
Rosales I Courtyard by Marriot Madrid Princesa Hotel

1:30pm

Lunch Break in Exhibition
Tuesday September 19, 2017 1:30pm - 2:30pm
Rosales 2+3 Courtyard by Marriot Madrid Princesa Hotel

2:30pm

Session 2: Screens
Thanks to recent advances in cell culture and imaging technologies, high content screenings are now reaching a critical point where they can be realistically deployed at large scale, opening exciting opportunities for industry and academia. This section aims to gather worldwide experts involved in every aspects of this promising field to share their recent achievements and vision of the future.

2:30 - 3:00
Filling the Drug Discovery Gap: Is HCS the Missing Link?
Jean-Philippe Stéphan, SERVIER

Despite the fact that many drugs on the market today were discovered through phenotypic screens, this approach is considered by many investigators as a “black box” and in many cases target centric biochemical or cellular assays are preferred to support the initial drug discovery steps. Nevertheless, this “white box” approach clearly does not deliver all the expected success in term of drug developments, mostly due to the lack of pathophysiological relevance of the models. Now, the pharmaceutical industry is implementing new discovery paradigms to try to solve the current disconnect between the drug discovery process and the human clinical trials. Among the myriad of new technologies and approaches currently considered, High Content Screening combined with biosensors technologies, genome-editing and stem cell-derived cellular models offer the opportunity to drastically transform phenotypic screening, linking target engagement and phenotypic impacts in more relevant in vitro models. This new generation phenotypic screens combined with the current drug discovery strategies represent a true opportunity to fulfill the gap between the screening dish and the patients. Despite the tremendous potential of HCS, researchers have to carefully consider various aspects of the projects before deploying the technology and this presentation will go through several examples highlighting the current strengths and weaknesses of the approach.    

3:00 - 3:30  
Imaging Phenomics for the Discovery of Next-Generation Anti-Virals
Steffen Jaensch, Janssen Pharmaceutica

Several proof-of-concept studies have demonstrated that unbiased pheno-signatures derived from high-content imaging data provide a powerful tool to characterize the mechanism-of-action of small molecules in a cellular context. Such signatures can be generated at an early stage of the drug discovery pipeline and provide valuable information to guide, for example, the selection of lead compounds from high-throughput screening hits. We have employed such a phenomics approach for the discovery of novel anti-viral compounds. We established an imaging assay and computational pipeline to generate pheno-signatures that capture the infection state and morphological characteristics of single cells under compound treatment. The signature of non-infected untreated cells describes the most desirable phenotypic state that an ideal inhibitor should revert infected cells back to. We validated our approach with annotated reference compounds and found that we can distinguish host-factor targeting from direct anti-viral compounds with near perfect accuracy. Our method can also distinguish several sub-categories of direct anti-viral mechanisms such as replication vs. entry inhibitors. This greatly reduces the need for costly and time-consuming follow-up assay cascades.

3:30 - 4:00 
High-content phenotypic screening using disease relevant, human, primary cells – Identifying and profiling diverse compounds for cardiac regeneration
Erik Müllers, AstraZeneca

Heart failure is incapacitating and currently incurable. It is thought that activation and proliferation of resident cardiac progenitor cells, i.e. EPDCs has therapeutic potential to help repair the heart after injury. However, drug discovery approaches have so far been impeded by lack of well-defined screening platforms and poor understanding of the molecular mechanisms regulating EPDC activation, proliferation and differentiation. In areas of novel and complex pharmacology high-content phenotypic screening is particularly attractive to identify starting points for potential therapeutics in an unbiased fashion, as well as to aid target deconvolution and mechanism of action activities. We developed and validated a high-throughput, phenotypic screen for compounds selectively proliferating EPDCs while maintaining the progenitor phenotype. Following from the primary screen and respective counter screens we identified and validated hits representing more than 20 different chemical clusters. For a few of these cluster we could identify primary targets. To further aid target identification and mode of action studies we applied a high-content image-based assay for morphological profiling, i.e. Cell Painting, to our EPDC screening campaign. The assay was implemented in 384-well format, using automated liquid handling, high-throughput microscopy, and automated image analysis on a high-performance computing cluster. Building on available image analysis pipelines for nucleus, cell and cytoplasm we developed additional segmentation of endoplasmic reticulum and nucleoli. From the segmented objects thousands of cellular features were extracted and analysed using clustering algorithms resulting in morphological fingerprints of donor populations, and effects of compound treatment. In summary, we developed a high-throughput phenotypic screen as well as a high-content phenotypic screen using relevant human primary cells. We used the assays to identify starting points for drug discovery projects, to better understand mechanism of action, and to deconvolve primary drug targets.

4:00 - 4:30
Genome-wide RNAi screening combined with high content imaging to dissect membrane traffic pathways in mammalian cells
Jez Simpson, University College Dublin

The endomembrane system of mammalian cells has a unique architecture allowing it to carry out a large number of specialised biochemical reactions in parallel. The function of these organelles is dependent on highly regulated intracellular transport events between them. We are using a systematic approach of genome-wide RNA interference screens combined with high-content screening (HCS) microscopy, specifically applying texture feature analysis and machine learning, to quantitatively map these transport pathways and identify their regulators. In this seminar I will describe how this approach has revealed novel regulators of the endomembrane system, and regulators of how nanoparticles (as surrogate drug delivery vectors) enter and traffic through cells. I will also discuss some of the challenges associated with transitioning membrane traffic assays between 2D and 3D cell culture formats.
Overall, the information that we gather provides a deeper systems-level view of how cells are organised, and provides knowledge fundamental to the design of next generation drug delivery vectors and biomedical devices. 

[1] Galea G, Bexiga MG, Panarella A, O'Neill ED & Simpson JC (2015). A high-content screening microscopy approach to dissect the role of Rab proteins in Golgi-to-ER retrograde trafficking. J. Cell Sci., 128(13), 2339-2349.
[2] Panarella A, Bexiga MG, Galea G, O' Neill ED, Salvati A, Dawson KA & Simpson JC (2016). A systematic High-Content Screening microscopy approach reveals key roles for Rab33b, OATL1 and Myo6 in nanoparticle trafficking in HeLa cells. Scientific Reports, 6, 28865.

4:30 - 5:00 
Automated microscopy and image-based analysis for functional genomics
Michael Boutros, German Cancer Research Center (DKFZ) and Heidelberg University

Image-based screening is used to measure a variety of phenotypes in cells and whole organisms. Combined with perturbations such as RNA interference, small molecules, and mutations, such screens are a powerful method for gaining systematic insights into biological processes. High-throughput screens have been applied to study diverse processes, such as protein-localization changes, cancer cell vulnerabilities, and complex organismal phenotypes. Recently, advances in imaging and image-analysis methodologies have accelerated large-scale perturbation screens. As part of the presentation, I will discuss the design and execution of image-based screening experiments, and challenges in the analysis of large-scale image based data sets. I will particularly focus on using image-based approaches in phenotypic drug discovery and in the analysis of genetic interaction networks. Furthermore, I will discuss applications of image-based screens in patient-derived organoids.

 Breinig, M., Klein, F., Huber, W., Boutros, M. (2015). A chemical-genetic interaction map of small molecules using high-throughput imaging in cancer cells. Molecular Systems Biology 11:846.

Boutros, M., Heigwer, F., Laufer, C. (2015). Microscopy-based high content screening. Cell 163:1314-1325.


Vendor Snapshots:

  • Idea Bio, Presenter: Jason Otterstrom
  • Wako, Presenter: Andreas Chamber

...

Speakers
avatar for Michael Boutros

Michael Boutros

German Cancer Research Center (DKFZ) and Heidelberg University
Michael Boutros is Professor at Heidelberg University and Head of the Division of Signaling and Functional Genomics at the German Cancer Research Center (DKFZ). His research group works on experimental and computational approaches for image-based phenotypic screens with a particular focus on genetic and chemico-genetic interaction... Read More →
avatar for Steffen Jaensch

Steffen Jaensch

Senior Scientist, Johnson & Johnson
Dr. Steffen Jaensch works at Janssen Pharmaceutica, Pharmaceutical Companies of Johnson & Johnson, in Beerse, Belgium. He is responsible for the analysis of imaging assay development and screening data for drug discovery and target identification projects with a focus on establis... Read More →
avatar for Erik Müllers

Erik Müllers

Senior Research Scientist - Mechanistic Biology & Profiling, AstraZeneca
Erik Müllers works within the global Discovery Sciences organization at AstraZeneca. He focusses on novel cell-based, imaging-based assays and image analysis strategies to support drug discovery and target identification projects at an early stage of the drug discovery pipeline. Dr... Read More →
avatar for Jez Simpson

Jez Simpson

Jeremy Simpson carried out his PhD at the University of Warwick (UK). After post-doctoral work at the Scripps Research Institute (San Diego, USA) and the ICRF (London, UK), a long term EMBO fellowship took him to the EMBL (Heidelberg, Germany), where he developed and applied novel high-throughput imaging approaches to study protein localisation and membrane traffic. In 2008 he was appointed as Professor of Cell Biology at University College Dublin, Ireland. His lab applies high-throughput imaging technologies to study intracellular trafficking pathways, the internalisation routes taken by synthetic nanoparticles on exposure to cells, and how cells respond to nanomaterials and nanosurfaces. He has authored over 90 peer-reviewed articles, including articles in Nature Cell Biology, Nature Communications and Nature Methods, and runs the UCD Cell Screening Laboratory (www.ucd.ie/hcs). He is currently the Head of School of Biology... Read More →
avatar for Jean-Philippe Stephan

Jean-Philippe Stephan

Head of Models & HTS department, Institut de Recherches Servier
Jean-Philippe Stéphan, originally from Rennes, Brittany, France, received his Ph.D. in Developmental Biology from Pierre and Marie Curie University (Paris VI, France). After a postdoctoral fellowship at Genentech, he was hired as a Research Scientist in the Assay and Automation Technology department (AAT) at Genentech, Inc. Over his 17 years tenure at Genentech, Dr... Read More →


Tuesday September 19, 2017 2:30pm - 5:00pm
Rosales I Courtyard by Marriot Madrid Princesa Hotel

5:00pm

Coffee Break in Exhibition
Tuesday September 19, 2017 5:00pm - 5:30pm
Rosales 2+3 Courtyard by Marriot Madrid Princesa Hotel

5:30pm

Poster Presentation Talks
Select poster presenters will be invited to present their poster content in a snapshot presentation. 

John Bassett | School of Pharmacy, The University of Queensland 

Monitoring Altered Ca2+ Signalling in Breast Cancer Cells with a High-Content Imaging Model of Intracellular Ca2+ Dynamics Using Genetically Encoded Calcium Indicators Expressed in MDA-MB-231 Breast Cancer Cells. (Poster 02)

 

Aurianne Lescure| Institut Curie -Translational Research Department 

Using Cell-Based High-Content Screening in Combination with X-irradiation for the Identification of Novel Glioblastoma Radiosensitizing Agents. (Poster 03)

 

Miguel Sanchez-Alvarez | CNIC

Automated Quantitative Imaging Tools for the Study of Organelle Homeostasis and Interorganelle Communication. (Poster 04)

 

Jessica Taylor | University of Manchester

High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of recurrent glioblastoma. (Poster 07)

 

Hester Bange | Leiden University/OcellO     

A 3D High-Content Screening Assay as New Model System for Polycystic Kidney Disease.(Poster 10)

 

Carmen Ramos | Fundación Medina

High-Content Biomaging in Drug Discovery and Safety at Medina (Poster 19)

 

Amy Sawtell | UCB

A High-Throughput High-Content In Vitro Primary Cell Screen for Novel Anti-Fibrotics. (Poster 20)

 

Saman Honarnejad| Pivot Park Screening Centre 

Image-based compound profiling in cell based assays (Poster 23)

 

Bogdan Mazoure| McGill University and Université du Québec à Montréal

Identification and Correction of Spatial Bias are Essential for Obtaining Quality Data in High-Throughput Screening Technologies (Poster 27)  

 


Tuesday September 19, 2017 5:30pm - 6:30pm
Rosales I Courtyard by Marriot Madrid Princesa Hotel

6:30pm

Networking Reception in Exhibition
Tuesday September 19, 2017 6:30pm - 8:00pm
Rosales 2+3 Courtyard by Marriot Madrid Princesa Hotel

8:00pm

Delegates and Exhibitor Networking Dinner

Join us for this hosted reception on Tuesday 19 September starting at 8:00 p.m. on the terrace of the Courtyard Madrid.  Tapas-style food, drink and networking with your peers and colleagues are on the menu.

This networking dinner is included with your event registration.  


Tuesday September 19, 2017 8:00pm - 10:00pm
Terrace
 
Wednesday, September 20
 

7:00am

High Content Sightseeing: Walking/Running Tour “Madrid de Los Austrias”
We will get the feel of what living in the old town of Madrid might have been like in the 16th century period, when the Habsburg dynasty (named Los Austrias) first designated it as the Spanish capital promoting the development of the city. The tour will start in “Plaza de Oriente”, where the Arabs’s fortress against Christian incursions set the origin of Madrid city. These beautiful gardens are now surrounded by the Royal Theater and Palace which were built later in the 19th century.

We will walk around the adjoining back streets which make up the irregular layout of what was once a Medieval town sprinkled with coaching inns, convents and palaces. We will end up visiting “Plaza Mayor” (main square) which was used as a marketplace on weekdays and was the scene of popular events from bullfights to public executions of Inquisition. Those willing to take new risks (at least for their arteries) on the way back to the Hotel can have a taste of the most famous Spanish breakfast “chocolate con churros” served since 1894 at the “Chocolateria San Ginés” canteen.

The pace will be easy, but please dress appropriately for an approximately 10K route.


Wednesday September 20, 2017 7:00am - 8:15am
Lobby Courtyard by Marriot Madrid Princesa Hote

8:00am

Registration Open
Wednesday September 20, 2017 8:00am - 3:30pm
Foyer Courtyard by Marriot Madrid Princesa Hotel

8:30am

Morning Coffee Break
Wednesday September 20, 2017 8:30am - 9:00am
Foyer Courtyard by Marriot Madrid Princesa Hotel

8:30am

Exhibition Open
Wednesday September 20, 2017 8:30am - 3:45pm
Rosales 2+3 Courtyard by Marriot Madrid Princesa Hotel

9:00am

Session 3: Data Analysis
The analysis of the large amount of data generated high content screening experiments represents a significant challenge and is currently a bottleneck in many small molecules and genetic screening projects.  This section is an exciting opportunity for reviewing the main challenges in interpreting complex high-content screening data, including key informatics and data analysis approaches such as image descriptors computations and classification algorithms.

9:00 - 9:30 
Computational methods for fluorescence microscopy and quantitative bioimaging
Charles Kervrann, Senior Researcher, Inria Rennes - Bretagne AtlantiqueSEPICO Project-Team 

During the past two decades, biological imaging has undergone a revolution in the development of new microscopy techniques that allow visualization of tissues, cells, proteins and macromolecular structures at all levels of resolution. Thanks to recent advances in optics, digital sensors and labeling probes, one can now visualize sub-cellular components and organelles at the scale of a few dozens nanometers to several hundreds of nanometers. As a result, fluorescent microscopy and multimodal imaging has become the workhorse of modern biology. All these technological advances in microscopy, created new challenges for researchers in quantitative image processing and analysis. Therefore, dedicated efforts are necessary to develop and integrate cutting-edge approaches in image processing and optical technologies to push the limits of the instrumentation and to analyze the large amount of data being produced.In this talk, we present image processing methods, mathematical models, and algorithms to build an integrated imaging approach that bridges the resolution gaps between the molecule and the whole cell, in space and time. The presented methods are dedicated to the analysis of proteins in motion inside the cell, with a special focus on Rab protein trafficking observed in time-lapse confocal microscopy or total internal reflection fluorescence microscopy. Nevertheless, the proposed image processing methods and algorithms are flexible in most cases, with a minimal number of control parameters to be tuned. They can be applied to a large range of problems in cell imaging and can be integrated in generic image-based workflows, including for high content screening applications.

9:30 - 10:00 
Big data approaches for computational phenotyping
Thomas Walter, MINES ParisTech 

In High Content Screening (HCS) we dispose of the technological tools to perform imaging experiments at an unprecedented scale and thus to generate extremely large and complex image data sets, that can be readily qualified as “big data”. In this context, methods from computer vision and machine learning have been instrumental to deal with the generated large-scale image data sets. After a short review of computer vision techniques for computational phenotyping for live cell imaging data, I will present recent developments in the field of spatial transcriptomics, where we aim at understanding the spatial aspects of gene expression at a large scale. This poses interesting and challenging questions for the analysis of such data: single RNAs can be automatically detected and their spatial distribution analyzed with newly designed features and machine learning methods. Importantly, as there is little prior knowledge available for this type of data, we have built a virtual cell environment in order to simulate RNA localization patterns inside cells to validate the developed methods. More generally, simulation frameworks are becoming increasingly important for computational phenotyping. Finally, I will present new approaches to analyze and computationally phenotype cells in their tissular context. Segmentation is one of the major bottlenecks in computational phenotyping of histopathology data. Here, I present a new technique for the segmentation and classification of nuclei based on deep learning. This method allows us to analyze large cohorts of patient data with respect to their cellular and tissular phenotypes and to relate these descriptors to clinical variables.

10:00 - 10:30
Active-learning strategies for high content imaging screening using complex in vitro models 
Alejandro Amador, GSK

The analysis of physicochemical properties during compound optimization is critical to identify candidate drug quality and safety issues. Without the proper biological systems in place and ADME (absorption, distribution, metabolism and excretion) characteristics, many clinical leads have failed to achieve desired target exposure, pharmacological response and/or safety margins in humans. Numerous parameters affect the prediction of the efficacy of a drug on the body. However, the persistent failures to translate promising preclinical candidates into clinical success highlight detachment from clinical practice during assay validation. In fact, much of the drug screening process is done with cells plated as two-dimensional (2D) monolayer on the bottom of microplate wells. A growing amount of work has shown that the use of three-dimensional (3D) in vitro models in combination and active learning processes present a novel and potentially high-value de-risking strategy. To help address these issues, our group is engaging into multidisciplinary collaborations to develop novel preclinical models and cell-based screening technologies to improve clinical relevance. We are designing and building an intelligent, automated platform to accelerate the identification of high value small molecule leads, and the delivery of quality candidates into clinical development. In this presentation, I will introduce a high-content imaging based 3D tumor in vitro model that our group is using for testing oncology drugs. In addition, I will talk about some of the challenges we are facing when analyzing multiparameter data of large number of images with various computational active-learning approaches.

10:30 - 11:00
The analysis of image-based CRISPR-Cas9 gene perturbation screens
Reinoud de Groot, IMLS, University of Zürich

CRISPR-Cas9 has emerged as a powerful tool for functional genomic screening. The large-scale CRISPR-Cas9 screens performed to date have used a pooled screening format, precluding image-based phenotyping of individual cells. We set out to develop methods for arrayed, image-based CRISPR-Cas9 screening. To this end, we developed a pipeline for high throughput generation of CRISPR-Cas9 targeting plasmids to construct an arrayed screening library of approximately 2200 plasmids targeting ubiquitin ligases, kinases and phosphatases. We performed an image-based screen for genes affecting the subcellular localization of a marker of the nuclear pore complex. I will discuss how we exploited the experimentally induced genetic mosaicism for the analysis of this large-scale, image-based, functional genomic screening experiment. Our data analysis strategy allowed us to identify the perturbations that cause phenotypic changes in individual cells and subsequently select the phenotypically perturbed cells for further analysis.

11:00 - 11:30
Exploring Toxicity Profiling for Drug Screening using Deep Learning Strategies
Daniel Jimenez, Centro Nacional de Investigaciones Cardiovasculares (CNIC)

Toxicity is a major factor of failure in drug development, causing costly withdrawals of drugs from the market. Efficienct drug discovery could be greatly improved if compounds with cytotoxic characteristics were identified during primary screening campaigns. Although apoptotic & necrotic processes involve dramatic changes in cell morphology, these have never been exploited for systematic and quantitative assessment of cellular toxicity due to lack of methods to identify them in a reproducible manner. The development of high-content imaging platforms has allowed the incorporation of complex toxicity counter-screens. However, this requires expensive and lengthy labelling of cytotoxicity specific reporters. There is thus an urgent need to develop cost-effective methods for toxicity assessment qualified for high throughput screening (HTS). We hypothesize that toxicity could be detected without toxicity specific labelling by using state of the art computer vision methods, thus reducing significantly the cost of drug screens. In this work we develop a framework to determine cell cytotoxicity status as a HTS readout based on the analysis of nuclear fluorescence microscopy images by using deep learning strategies. Multiple cell-based assays including concentration-response curves for drugs with different cytotoxic effects are used for training and validation of the system. Preliminary results support our hypothesis, reporting high correlations between toxicity predictions, dose-response curves, and well-established cytotoxicity reporters; suggesting that the automatic pattern recognition performed by deep neural networks is able to detect differential structural and nuclear-based features related with the cytotoxic state of the cells. Therefore, this framework has the potential to become a new scientific breackthrough for toxicity assessment in drug screening.

Vendor Snapshots: 
  • GENEDATA, Presenter: Matthias Fassler

...

Speakers
avatar for Alejandro Amador

Alejandro Amador

Scientific Leader - Platform Biology Automation, GSK
Alejandro Amador studied biology at the Autonomous University of Barcelona (Barcelona, Spain). He obtained his PhD in the laboratory of Dr. Mara Dierssen at the Center for Genomic Regulation (CRG, Barcelona, Spain), where he worked with mouse models of Panic disorder and... Read More →
avatar for Reinoud de Groot

Reinoud de Groot

Reinoud de Groot studied biology at Utrecht University, the Netherlands. He joined the lab of prof. H.C. Korswagen to investigate the mechanisms of Wnt signaling and Wnt secretion and obtained his PhD in 2014. He subsequently joined the lab of prof. L. Pelkmans at the University of... Read More →
avatar for Charles Kervrann

Charles Kervrann

Inria Senior Researcher, Inria Rennes - Bretagne Atlantique
Charles Kervrann received the M.Sc. (1992), the PhD (1995) and the HDR (2010) in Signal Processing and Telecommunications from the University of Rennes 1, France. From 1997 to 2010, he was researcher at the INRA Applied Mathematics and Informatics Department (1997-2003) and he... Read More →
avatar for Thomas Walter

Thomas Walter

Thomas Walter has been working in the field of biomedical image analysis for more than 15 years. His most visible scientific contributions have been in the field of High Content Screening (HCS). He has pioneered methods in the field of cellular phenotyping for live cell imaging d... Read More →


Wednesday September 20, 2017 9:00am - 11:30am
Rosales I Courtyard by Marriot Madrid Princesa Hotel

11:30am

Coffee Break in Exhibition
Wednesday September 20, 2017 11:30am - 12:00pm
Rosales 2+3 Courtyard by Marriot Madrid Princesa Hotel

12:00pm

Session 4: Model Systems
The selection of a suitable model system is critical in the successful advancement of novel therapeutic approaches to disease. The development of models and assays that recapitulate the full complexity of the disease they intend to represent, and the ability to scale them up to screening campaigns remains a big challenge in the field. The session will bring together experts in the field presenting innovative models across different disease areas. 

12:00 - 12:30
Kinetic phenotypic screening to mine the transcriptome of iPSC-cardiomyocytes for therapeutic targets and drive medicinal chemistry drug optimization
Mark Mercola, Stanford University 

Current drug therapies to treat heart failure act through relatively few targets, and heart failure continues to be a major cause of mortality worldwide. The cost of new medicines continues to skyrocket, arguably because of the high failure rate and lack of innovative and selective new targets.  Patient iPSC-derived cardiomyocytes hold tremendous promise for creating better drugs since it is theoretically possible to introduce aspects of the patient’s clinical presentation into the earliest stages of the drug discovery process, and conduct unbiased screens to decipher disease mechanisms and identify drugs that work by completely novel mechanisms.  We have enabled this process by developing high throughput kinetic screens of cardiomyocyte physiology that read out parameters of arrhythmia and contractility.  Our focus is on developing new therapies for cardiac arrhythmia, which is estimated to be involved in over half of all cardiac-related deaths.  Examples of the use of this technology to support the medicinal chemistry optimization of a small molecule anti-arrhythmic drug and to probe target space for novel arrhythmia susceptibility loci and new anti-arrhythmia targets will be described. 


12:30 - 1:00 
High Content Screening of Patient Specific Tumour Cells: Towards Personalised Treatment in Recurrent Glioblastoma Multiforme
Jessica Taylor, University of Manchester

1:00 - 1:30 
Fishing out new drugs
Christian Helker, Max Planck Institute

Historically, screens to identify small molecules are done through target and phenotypic based in vitro screens.  However, the identified drugs often fail in the preclinical animal model for two main reasons: 1) pharmacokinetics at the whole organism level, including the absorption, distribution, metabolism, and excretion (“ADME”) properties of small molecules2) cytotoxicity and side/off target effects.  These complexities hinder the extrapolation of drug-target interactions in vitro to pharmacological actions in vivo, resulting in more than 70% of compounds in oncology to fail in phase II clinical trials, while 59% of the remaining compounds are discarded in phase III due to intolerable toxicities.Considering these challenges, developing tools for rapid, cost-efficient and translational small-molecule discovery in whole organisms greatly strengthens the translation potential in novel drug discovery. Zebrafish embryos are amenable to semi high-throughput chemical screens combining the advantages of the scale of in vitro screens with the physiological complexity of a developing animal. Using the zebrafish as an in vivo system for drug discovery has several unique advantages: (i) the low cost per animal, (ii) ease of genetic manipulations  (iii) small body size enables to screen zebrafish larvae in 96-well plates (iv) large progeny of embryos to ensure high throughput of large chemical libraries (v) as a vertebrate, the zebrafish shares a similar body plan to mammals and genetic and molecular pathways that drive organ development are conserved to humans Altogether, this brings the zebrafish in a prominent position as an affordable and feasible model system to perform high throughput in vivo screens.  

1:30 - 2:00 
Collaborative Phenotyping at King's College London: HipSci and the Stem Cell Hotel
Davide Danovi, King's College London, Director, HipSci Cell Phenotyping

A clear understanding of the limitation of the current approaches in Drug Discovery is emerging throughout academia and industry. Efforts incorporating relevant cells, advanced cell culture techniques, artificial microenvironment, imaging and data analysis are moving forward allowing unprecedented opportunities in the modelling of diseases and identification of targets and therapies. The HipSci project brings together the Wellcome Trust Sanger Institute, the University of Dundee, King’s College London and the European Bioinformatics institute. A large panel of hundreds of cell lines reprogrammed from adult cells donated by healthy volunteers and patients are being fully characterised in genomics, proteomics and cell behaviour. We work within this framework at the Centre for Stem Cells and Regenerative Medicine directed by Fiona Watt at King’s College London. We have established assays for imaging of induced pluripotent stem cells and are also developing solutions to integrate dynamic and end-point high content data with the other datasets provided by the partner centres in the project. The expertise in stem cell biology, image analysis and engineered substrates as well as access to specialised equipment are now opening to interested scientists through a dedicated collaborative phenotyping space, the Stem Cell Hotel.

2:00 - 2:30 
Phenomics in the precision medicine of solid tumors
Vilja Pietiäinen, Institute for Molecular Medicine Finland FIMM

Our aim is to gain better understanding of the cancer biology and eventually to tailor drugs for patients by extensive -omics profiling of cancer patient -derived cells (PDCs) and tissues. In addition to genetic profiling of original tumor tissues, the developed PDC models are characterized with genomics, image-based phenotyping (phenomics) and high throughput drug profiling. Here, we present how these methods are applied in our precision medicine project on solid tumors, specifically renal cancer. First, the original tumor tissue and the PDCs are analyzed by exome sequencing to ensure that somatic driver mutations and copy number variations are shared between the tissue and corresponding cell models. This is followed by phenomics approach, which allows comprehensive phenotypic characterization of tissues and ex vivo cell cultures, detection of biomarkers at very early stages, and functional analysis of drug responses at the single cell level. For the image-based drug profiling, the PDCs are treated with a library of >500 oncology compounds in five different concentrations, immunostained, and subjected to automated high-content imaging and image analysis. The features extracted from single cells are used for phenotypic classification based on machine learning to provide information on drug effects on the different cellular phenotypes. In our proof-of-concept study of clear cell renal carcinoma, PI3K/mTOR pathway inhibitors were found to be among the drugs inhibiting the proliferation of renal cancer PDCs, in agreement with detected somatic mutations affecting these pathways. In addition, our image-based drug sensitivity testing revealed the intra-sample heterogeneity in drug sensitivity and resistance. We are now further investigating the mechanisms of most potent drugs and their combinations in PDCs at single cell level. As a conclusion, our results implicate the importance of genomics and phenomics in comprehensive characterization of PDCs, and how phenomics enables the scoring of drug responses in heterogenic cancer cell cultures. We foresee that these approaches may potentially improve the translation of results back to clinic and support the design of combination therapies in cancer.

Vendor Snapshot:
  • Labcyte, Presenter: Aurore Lejeune-Dodge

Speakers
avatar for Davide Danovi

Davide Danovi

Director, HipSci Cell Phenotyping, King's College London
Dr. Davide Danovi is leading the HipSci Cell Phenotyping group at the Centre for Stem Cells and Regenerative Medicine at King's College London in the framework of the Wellcome Trust and MRC funded HipSci project. | | Davide holds an MD from the University of Milan and a PhD in ... Read More →
avatar for Mark Mercola

Mark Mercola

Stanford Cardiovascular Institute and the Department of Medicine, Stanford University
Dr. Mercola is Professor of Cardiovascular Medicine at Stanford and a member of the Stanford Cardiovascular Institute.  Prior to Stanford University, he was on the Associate Professor of Physiology at Harvard Medical School, and later Professor of Bioengineering at the University of California, San Diego, and also at the Sanford-Burnham-Prebys Medical Research Institute. He co-founded the Prebys Center for Drug Discovery (at the Sanford-Burham-Prebys Medical Research Institute), which operated as one of large screening centers of the NIH Molecular Libraries screening initiative. He serves on multiple editorial and advisory boards, including Vala Sciences (San Diego), Stem Cell Theranostics (Redwood City, CA) and the Human Biomolecular Research Institute (San Diego... Read More →
avatar for Vilja	Pietiäinen

Vilja Pietiäinen

Senior Scientist, FIMM/University of Helsinki


Wednesday September 20, 2017 12:00pm - 2:30pm
Rosales I Courtyard by Marriot Madrid Princesa Hotel

2:30pm

Closing Lunch in Exhibition
Wednesday September 20, 2017 2:30pm - 3:45pm
Rosales 2+3 Courtyard by Marriot Madrid Princesa Hotel

2:40pm

Poster Presentations in Exhibition
Poster presenters will be available at their individual posters to answer questions and present content.  

Poster 01 – In Vitro Assessment of Drug Effects on Human iPSC-Derived Cardiac Spheroid Cultures; Geoff Dance, Molecular Devices

 

Poster 02 – Monitoring altered Ca2+ signalling in breast cancer cells with a high-content imaging model of intracellular Ca2+ dynamics using genetically encoded calcium indicators expressed in MDA-MB-231 breast cancer cells; John Bassett, School of Pharmacy, The University of Queensland

 

Poster 03 – Using cell-based high-content screening in combination with X-irradiation for the identification of novel Glioblastoma radiosensitizing agents; Aurianne Lescure, Institut Curie - Translational Research Department

 

Poster 04 – Automated quantitative imaging tools for the study of organelle homeostasis and interorganelle communication; Miguel Sanchez-Alvarez, CNIC

 

Poster 05 – CANCELLED: High-content screening: picturing microRNAs in cardiovascular diseases; Miguel Mano, University of Coimbra, Portugal

 

Poster 06 – High-Content High-Throughput Assays for Morphological Characterization of Neuronal Development in 3D Matrix Using Human iPSC-Derived Neuronal Cultures; Alexandre Fouassier, Axiogenesis AG

 

Poster 07 – High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of recurrent glioblastoma; Jessica Taylor, University of Manchester

 

Poster 08 – Harnessing complexity for easy and robust gene silencing with siPOOLs; Catherine Goh, siTOOLs Biotech GmbH

 

Poster 09 – An Innovative Workflow for Practical Use of Deep Learning in Image-based Research; Stephan Steigele, Genedata AG

 

Poster 10 – A 3D High-Content Screening assay as new model system for polycystic kidney disease; Hester Bange, Leiden University/OcellO

 

Poster 11 – High Content Screening cell based assays for deciphering mechanotransduction-driven mechanisms of tumour invasion; Antonio Quílez-Álvarez, CNIC

 

Poster 12 – The Phenomics Discovery Initiative (PDi) – A Model for Maximising the Translational Impact of Biological Research; Denise Barrault, National Phenotypic Screening Centre - NPSC

 

Poster 13 – CANCELLED: High Trhoughput target miRNA Screening; Sarantis Chlamydas, Active Motif

 

Poster 14 – The ZeCardio platform: High-throughput cardiotoxicity screening with zebrafish embryos; Sylvia Dyballa, ZeClinics SL

 

Poster 15 – Adoption of High Content Imaging Capabilities in Support of Integrated Drug Discovery Programmes; Marie Fisher, Sygnature Discovery

 

Poster 16 – A High Content Imaging Platform to Advance Target and Compound Validation Imaging Spines and Synapses for Neurological Disorders; Tim Kroecher, Evotec AG

 

Poster 17 – Establishment of breast cancer cells panel for drug repurposing; Carlos Marugán, Lilly

 

Poster 18 – Cell Health Assay Data from a Phenotypic Screen Correlates with Reported Liver Toxicity for FDA Approved Compounds; Michelle Newman, LifeArc

 

Poster 19 – HIGH CONTENT BIOIMAGING IN DRUG DISCOVERY AND SAFETY AT MEDINA; Carmen Ramos, Fundación Medina

 

Poster 20 – A high-throughput high-content in vitro primary cell screen for novel anti-fibrotics; Amy Sawtell, UCB

 

Poster 21 – A High Content Platform for In Vivo Imaging Studies: Characterization of HTT Inclusions in the zQ175 Mouse Model of Huntington´s Disease; Carina Wollnik, Evotec AG

 

Poster 22 – High Throughput Multiplexed Apoptosis Assays Using the Labcyte Echo® Liquid Handler and the IntelliCyt iQue® Screener HD; Aurore Lejeune-Dodge, Labcyte GmbH

 

Poster 23 – Image-based compound profiling in cell based assays; Saman Honarnejad, Pivot Park Screening Centre

 

Poster 24 – CANCELLED: BioDataAnalysis CellAnalyzer uncovers complex cellular phenotypes of infection; Mario Emmenlauer, BioDataAnalysis GmbH

 

Poster 25 – TUMOR CELL INVASION ESTIMATION FROM 3D BIOIMAGE USING GEOMETRICAL INFORMATION AND UNSUPERVISED MACHINE LEARNING FOR HCS; Laura Fernández-de-Manuel, Centro Nacional de Investigaciones Cardiovasculares

 

Poster 26 – Analysis of high-dimensional transcriptomics data yields gene networks with high phenotypic discrimination power; Víctor Jiménez-Jiménez, CNIC

 

Poster 27 – Identification and correction of spatial bias are essential for obtaining quality data in high-throughput screening technologies; Bogdan Mazoure, McGill University and Université du Québec à Montréal

 

Poster 28 – High Performance Computing for High Content Screening Image Analysis – A Proof of Concept; Christian Schueller, PerkinElmer

 

Poster 29 – CANCELLED: 3D brain model of iPSC-derived neurons and glia for high-throughput neurotoxicity screening; Henriette Lanz, Mimetas


Poster 30 – High Content Imaging of 3D Cellular Models to Improve Drug Toxicity Risk Assessment, James Pilling, AstraZeneca


Wednesday September 20, 2017 2:40pm - 3:45pm
Rosales 2+3 Courtyard by Marriot Madrid Princesa Hotel
 
Thursday, September 21
 

8:30am

Registration Open
Thursday September 21, 2017 8:30am - 9:30am
Foyer Courtyard by Marriot Madrid Princesa Hotel

9:00am

SDDN Programming: Scientific Presentations
This year the SDDN / SLAS 2017 meeting has the theme "Case Studies in Drug Discovery and Development", and it will showcase several success stories, from academia, biotech, and pharma; opportunities, challenges, solutions and lessons learned will be highlighted. 

This programme is graciously sponsored by Promega

Welcome and opening remarks will be followed by three (3), 30-minute presentations

9:00-9:30 
José Antonio Enríquez, CNIC 

Here we will discuss on the partnership between CNIC/INOPHARMA on the definition of a new target for heart failure (HF). We present three different models of HF in mice: tachycardiomyopathy, HF with preserved left ventricular (LV) ejection fraction, and LV myocardial ischemia and hypertrophy. Regardless of whether LVEF is preserved or reduced, our results indicate that the three models share common molecular features: an increase in mitochondrial ROS, followed by ultrastructural alterations in the mitochondrial cristae and loss of mitoc­­hondrial integrity that lead to cardiomyocyte death. We show that the ablation of the mitochondrial protease OMA1 averts cardiomyocyte death in all three experimental HF models and thus plays a direct role in cardiomyocyte protection. This finding identifies OMA1 as a potential target for preventing the progression of myocardial damage in HF associated to a variety of etiologies. 

9:30-10:00 
Drug Discovery of allosteric inhibitors: the experience from Allinky
Miguel Vega, Allinky 

Allinky Biopharma is a biotech company-associated to academia-that focuses its activities on the discovery and development of small molecules to treat chronic inflammatory conditions, age-related degenerative diseases and cancer.

10:00-10:30
Bridging early academic research & clinical development on polypeptide-based nanomedicines
María Jesús Vicent, Polypeptide Therapeutic Solutions

PTS is a spin-off company from the Polymer Therapeutics Lab. headed by Dr Vicent at Centro de Investigación Príncipe Felipe (CIPF, Valencia, Spain) that devotes considerable efforts in R&D projects.  It was born trying to fill the gap between the research at the benchside and the big pharma within a very promising field polypeptide-based nanomedicines.

PTS aim to: a) the production and commercialisation of polypeptide-based systems (hydrogel and drug delivery systems) with structural & chemical diversity and functionality, but also well-defined architecture in terms of Mw and low polydispersities; b) development of polypeptide-based drug delivery systems for topical applications.

Very recently PTS has invested a large amount of human and economic resources to implement: i) a quality system following FDA and ICH guidelines for the manufacturing of pharmaceutical and cosmetic ingredients under GMP-compliant (not certified) quality grade; ii) Instrumental techniques and analytical developments to cover all the characterization required by ICH guideline Q6ASpecifications and iii) Up-scale manufacturing allowing to produce the polypeptides at Kg scale.

We have developed a cross-linked biopolymer hydrogel platform capable to enhance the permeation of actives to target skin layers. Moreover, the production under Good Manufacturing Process (GMPs) for cosmetic and therapeutic products for human beings has been the milestone for PTS along 2017 and will continue in 2018, for which PTS has built a structure to provide feasible translation from research products to clinical development and market.  


Speakers
avatar for José Antonio Enríquez

José Antonio Enríquez

CNIC
Dr. José Antonio Enríquez, has a wide experience in biogenesis and pathology of mtDNA. He obtained his PhD studying the expression of mtDNA in the departamento de Bioquímica (Universidad de Zaragoza) and supported by a D.G.A. fellowship. In 1992, started his post-doctoral training in CALTECH, under... Read More →
avatar for Miguel Vega

Miguel Vega

Miguel has a broad background in engineering and management, with specific training and expertise in molecular and cell biology, chemical and biochemical synthesis, industrial processing as well project design and implementation. For the last 20 years he has been involved in proj... Read More →
avatar for María Jesús Vicent

María Jesús Vicent

Team Leader (Polymer Therapeutics Laboratory-Scree, Centro de Investigación Príncipe Felipe
Dr. María J. Vicent received her Ph.D. degree in 2001 in chemistry on solid supports from University Jaume I after several scientific stays in Prof. Fréchet’s lab. at University California, Berkeley (USA). Then, she moved to more biomedically oriented research, initially with a Spanish company Instituto Biomar SA., and subsequently at the Centre for Polymer Therapeutics with Prof. R. Duncan after the award of a Marie Curie Postdoctoral Fellowship in 2002. In 2004... Read More →


Thursday September 21, 2017 9:00am - 10:30am
Rosales I Courtyard by Marriot Madrid Princesa Hotel

10:30am

Coffee Break: Sponsored by Promega
Thursday September 21, 2017 10:30am - 11:00am
Foyer Courtyard by Marriot Madrid Princesa Hotel

11:00am

SDDN Programming: Scientific Presentations
This year the SDDN / SLAS 2017 meeting has the theme "Case Studies in Drug Discovery and Development", and it will showcase several success stories, from academia, biotech, and pharma; opportunities, challenges, solutions and lessons learned will be highlighted. 

This programme is graciously sponsored by Promega

This session will include four, 30-minute presentations. 

11:00-11:30
Partnering to Face the Challenges of Drug Discovery for the Neglected World
Julio Martin, GlaxoSmithKline

Neglected diseases are understood as those diseases affecting populations in mainly low-income countries. Despite the neglect suffered in terms of funding, research and policy, they are a leading cause of mortality, chronic disability and poverty. Amongst them, Neglected Tropical Diseases (NTDs) are a group of infectious diseases categorized by the particular neglect they have suffered in terms of investment in control measures. NTDs are still lacking effective and safe treatments. Of the 850 new therapeutic products registered in 2000-2011, only 5 were indicated for NTDs, none of them being a new chemical entity (NCE)1. However, the global disease burden caused by NTDs is high. The lack of investment in drug discovery for NTDs has been partially due to the absence of economic incentives. The issue of poverty is central to the nature of NTDs, since these diseases not only are due to poverty but also contribute to it through their socioeconomic impact.
As a response to this unmet medical need of global health, we have adopted a Public-Private-Partnership operative model. In this context, pharma R&D activities are aligned to the main not-for-profit organizations or alliances. Our partnership model is based on three open innovation pillars: open lab (Tres Cantos Open Lab Foundation supports visiting scientists to develop their own research projects working hand to hand with GSK scientists), open source (our early discovery assets are publicly available) and IP pool (we adhere to WIPO principles).
1 B. Pedrique, N. Strub-Wourgaft, C. Some, P. Olliaro, P. Trouiller, N. Ford, B. Pecoul and J. H. Bradol, Lancet Glob. Health, 2013, 1, e371.


11:30-12:00 
The role of venture capital in the drug discovery and development process
Raúl Martín-Ruiz, Ysios Capital 

Start-up companies are, in many cases, the initial source of molecules that might eventually become safe, efficacious and commercially successful pharmaceutical products. Since the life sciences venture capital industry kicked-off back in the late 1970s, it became the main source of funds for financing those innovative companies until they reached the position to be acquired by a bigger player or to become publicly listed in the stock exchange markets.During this talk I will explain how venture capitalists work and which are the reasons between their positive and negative investment decisions. I will review the due diligence process of investment opportunities that they undertake, that covers the whole value chain from science to pricing and reimbursement. Contribution of venture capital to success stories in the biotech sector will also be discussed, as well as creative and innovative business models on top of the traditional ones.

12:00-12:30 
Amelia Martín Uranga, Farmaindustria 

I am going to explain the development of new drugs is currently immersed in a series of important changes that are related, among others, with the following aspects: The general reformulation in investments in R&D; The expiration of patent rights for drugs that have been major sales; The change in focus towards drugs of biological origin;  The ever more widespread trend to outsource part of research. The interest of the pharmaceutical industry in finding new drugs of biological origin is growing, and it needs to do so while maintaining costs are not very high, making attractive the approach of finding products in development in research centers or small start-up companies, in order to reach effective collaboration agreements with them. In this context and within the framework of the Spanish Technological Platform for Innovative Medicines, FARMAINDUSTRIA launched (in the context of open innovation) the Farma-Biotech program in 2011 with the aim of providing the necessary information and promoting potential cooperation agreements between pharmaceutical companies, small Spanish biotechnology companies and research centers, to take advantage in the best way possible of the results of the research conducted in research centers and hospitals, and the positive preclinical findings that were obtained by these small start-ups. The reception by public & private sector has been excellent from the start of the program, and 109 different stakeholders participated in 15 meetings carried out since then.

12:30-1:00
ASEBIO Drug Discovery Group. A Case study: Harnessing the Power of the Drug Discovery Community in Spain
Arsenio Nueda, Almirall / ASEBIO 

ASEBIO, the Spanish Bioindustry Association, brings together companies, associations, foundations, universities, research and technology centers carrying out biotechnology related activities in Spain. ASEBIO is integrated in EuropaBio (European Bioindustries Association) and is member of the CEOE (Spanish Confederation of Employer’s Organizations) and the SEBBM (Spanish Society for Biochemistry and Molecular Biology). The Drug Discovery Group of ASEBIO was created in June 2016 to promote networking, educational and strategic initiatives based on the expertise and capabilities of ASEBIO members covering the entire drug discovery value chain.

The Group’s activities are articulated around 3 main objectives: (i) Networking and “super-networking” activities through integration and coordination with national and international drug discovery networks, sharing initiatives, information and experiences of common interest. (ii) Educational outreach to the general public and particularly to young students seeking an academic or industrial scientific career in the field of drug discovery. (iii) Offering our capabilities and expertise as a strategic drug discovery bio-industry that can contribute to the risk prevention and emergency response initiatives currently coordinated by the Spanish Health Authorities.

Current activities of the group will be put into context as a case study illustrating the benefits that harnessing the experience, capabilities and networking base of the drug discovery community has both for society and the bio-industry in general.


Speakers
avatar for Julio Martin

Julio Martin

Head of Kinetoplastid Biology, Director, GSK
I am currently working at the Kinetoplastid Discovery Performance Unit of GSK R&D at Tres Cantos (Spain). Our remit is to discover and develop new chemical entities for the treatment of human diseases caused by kinetoplastid parasites such as Leishmania and Trypanosoma. Our strategy is based on open innovation and collaborative... Read More →
avatar for Raúl Martín-Ruiz

Raúl Martín-Ruiz

Ysios Capital
Raúl Martín-Ruiz is a Principal in Ysios Capital, a leading independent Spanish venture capital firm that provides private equity financing to human healthcare and life sciences companies. Prior to joining Ysios in 2008 he developed his career in Laboratorios Almirall, initially... Read More →
avatar for Arsenio Nueda

Arsenio Nueda

Head, Cell Systems, Almirall, S.A.
I have 18 years experience in the Pharmaceutical Industry and a previous 10 year track record in Academia. I obtained my PhD in 1995 under the direction of Angel Corbí (Hospital de La Princesa, Madrid) working in the characterization of human leukocyte integrin gene promoters. My... Read More →
avatar for Amelia Martín Uranga

Amelia Martín Uranga

Farmaindustria
Amelia is PHD  in Law, with a thesis on legal protection of biotechnological innovations. She joined FARMAINDUSTRIA in 2006 to manage the Spanish Technological Platform for Innovative Medicines, as Innovative Medicines Initiative mirror. She also is in charge of the coordination... Read More →


Thursday September 21, 2017 11:00am - 1:00pm
Rosales I Courtyard by Marriot Madrid Princesa Hotel

1:00pm

SDDN Sponsor Snapshot: Promega

Promega - Tools for Drug Discovery and Development

Maria Jurado Pueyo, Technical Service and Application Specialist Manager (Promega Biotech Ibérica)


Thursday September 21, 2017 1:00pm - 1:10pm
Rosales I Courtyard by Marriot Madrid Princesa Hotel

1:10pm

SDDN Programming: Roundtable Discussion
This year the SDDN / SLAS 2017 meeting has the theme "Case Studies in Drug Discovery and Development", and it will showcase several success stories, from academia, biotech, and pharma; opportunities, challenges, solutions and lessons learned will be highlighted. 

The morning's speakers will participate in a moderated roundtable discussion moderated by Ion Arocena, ASEBIO. 

This programme is graciously sponsored by Promega

Moderators
avatar for Ion Arocena

Ion Arocena

General Manager, ASEBIO, the Spanish Bioindustry Association.
Ion Arocena is currently the General Manager of ASEBIO, the Spanish Bioindustry Association. Ion has worked for long as an investment management executive, with deep knowledge of the Life Sciences market. He studied Biotechnology in Madrid and completed his studies with an executive MBA at EOI Business School. He worked at the Technology Transfer Office of the Universidad... Read More →

Speakers
avatar for José Antonio Enríquez

José Antonio Enríquez

CNIC
Dr. José Antonio Enríquez, has a wide experience in biogenesis and pathology of mtDNA. He obtained his PhD studying the expression of mtDNA in the departamento de Bioquímica (Universidad de Zaragoza) and supported by a D.G.A. fellowship. In 1992, started his post-doctoral training in CALTECH, under... Read More →
avatar for Julio Martin

Julio Martin

Head of Kinetoplastid Biology, Director, GSK
I am currently working at the Kinetoplastid Discovery Performance Unit of GSK R&D at Tres Cantos (Spain). Our remit is to discover and develop new chemical entities for the treatment of human diseases caused by kinetoplastid parasites such as Leishmania and Trypanosoma. Our strategy is based on open innovation and collaborative... Read More →
avatar for Raúl Martín-Ruiz

Raúl Martín-Ruiz

Ysios Capital
Raúl Martín-Ruiz is a Principal in Ysios Capital, a leading independent Spanish venture capital firm that provides private equity financing to human healthcare and life sciences companies. Prior to joining Ysios in 2008 he developed his career in Laboratorios Almirall, initially... Read More →
avatar for Arsenio Nueda

Arsenio Nueda

Head, Cell Systems, Almirall, S.A.
I have 18 years experience in the Pharmaceutical Industry and a previous 10 year track record in Academia. I obtained my PhD in 1995 under the direction of Angel Corbí (Hospital de La Princesa, Madrid) working in the characterization of human leukocyte integrin gene promoters. My... Read More →
avatar for Amelia Martín Uranga

Amelia Martín Uranga

Farmaindustria
Amelia is PHD  in Law, with a thesis on legal protection of biotechnological innovations. She joined FARMAINDUSTRIA in 2006 to manage the Spanish Technological Platform for Innovative Medicines, as Innovative Medicines Initiative mirror. She also is in charge of the coordination... Read More →
avatar for Miguel Vega

Miguel Vega

Miguel has a broad background in engineering and management, with specific training and expertise in molecular and cell biology, chemical and biochemical synthesis, industrial processing as well project design and implementation. For the last 20 years he has been involved in proj... Read More →
avatar for María Jesús Vicent

María Jesús Vicent

Team Leader (Polymer Therapeutics Laboratory-Scree, Centro de Investigación Príncipe Felipe
Dr. María J. Vicent received her Ph.D. degree in 2001 in chemistry on solid supports from University Jaume I after several scientific stays in Prof. Fréchet’s lab. at University California, Berkeley (USA). Then, she moved to more biomedically oriented research, initially with a Spanish company Instituto Biomar SA., and subsequently at the Centre for Polymer Therapeutics with Prof. R. Duncan after the award of a Marie Curie Postdoctoral Fellowship in 2002. In 2004... Read More →


Thursday September 21, 2017 1:10pm - 1:40pm
Rosales I Courtyard by Marriot Madrid Princesa Hotel

1:30pm

Networking Lunch: Sponsored by Promega
Thursday September 21, 2017 1:30pm - 3:00pm
Rosales 2+3 Courtyard by Marriot Madrid Princesa Hotel